p53 in clinical contexts: Yes or not?;p53 na prática clínica: Sim ou não?

Arquivos de Gastroenterologia

Volumn 43, Issue 1, 2006, Pages 6-7

  Ribeiro Jr , Ulysses ^a   Safatle Ribeiro, Adriana Vaz ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Colorectal neoplasms; Genes; p53; Polymorphism (genetics); Prognosis

Indexed keywords

PROTEIN P53;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 17P; CLINICAL PRACTICE; COLORECTAL TUMOR; EDITORIAL; GENETIC POLYMORPHISM; HUMAN;

EID: 33646678910     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032006000100004     Document Type: Editorial

References (18)

1. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell. 1989;57:1083-93.
2. Forones NM, Oshima C, Nanogaki S, Tanaka M, Barbosa V. Determinação da atividade proliferativa pelo Ki-67 e p53 em doentes com câncer colorretal. Arq Gastroenterol. 1999;36:122-6.
3. Hall PA, McCluggage WG. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol. 2006;208:1-6.
4. Hollstein MC, Sidranski D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
5. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazer ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Cin Cancer Res. 2004;10:5845-9.
6. Jurach MT, Meurer L, Moreira LF. Expression of the p53 protein and clinical and pathologic correlation in adenocarcinoma of the rectum. Arq Gastroenterol. 2006;43:14-9.
7. Lima JM, Serafim PVP, Silva IDCG, Forones NM. Estudo do polimorfismo genético no gene p53 (códon 72) em câncer colorretal. Arq Gastroenterol. 2006;43:8-13.
8. Lung FW, Lee TM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol. 2004;130:728-32.
9. Rawet V. Carcinoma colorretal: estadiamento e parâmetros prognósticos [tese]. São Paulo: Faculdade de Medicina da Universidade de São Paulo; 1998.
10. Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Puig P. Prognostic value of p53 mutations in rectal carcinoma. Int J Cancer. 2002;100:131-5.
11. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, Thomas G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer. 1992;66:758-64.
12. Ribeiro Jr U, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer. 1998;83:7-18.
13. Ribeiro Jr U, Alves VA, Souza PMSB, Safatle-Ribeiro AV, Rawet V, Nonogaki S, Gama-Rodrigues JJ, Habr-Gama A. Correlação das proteínas p53 e Ki67 com o prognóstico de pacientes com adenocarcinoma de reto distal. Rev Bras Coloproctol. 2000;20:248-56.
14. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518-28.
15. Sartor MC. Comparação entre a apoptose celular, a expressão do antígeno cárcino-embrionário e do p53 em pólipos colônicos benignos e câncer [tese]. São Paulo: Faculdade de Medicina da Universidade de São Paulo; 2000.
16. Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P, de La Chapelle A. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-4.
17. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-32.
18. Wynford-Thomas D. p53 in tumor pathology: can we trust immunocytochemistry? J Pathol. 1992;166:329-30.